Takeda's takhzyro® (lanadelumab) open label phase 3 study met its objectives in children ages 2 to

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the phase 3 shp643-301 study (nct04070326) evaluating the safety profile and pharmacokinetics (pk) of takhzyro® (lanadelumab) in patients 2 to
TAK Ratings Summary
TAK Quant Ranking